254 related articles for article (PubMed ID: 35212935)
1. Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies.
Vijayakumar D; Jankovic J
CNS Drugs; 2022 Apr; 36(4):327-343. PubMed ID: 35212935
[TBL] [Abstract][Full Text] [Related]
2. Initiation and propagation of α-synuclein aggregation in the nervous system.
Hijaz BA; Volpicelli-Daley LA
Mol Neurodegener; 2020 Mar; 15(1):19. PubMed ID: 32143659
[TBL] [Abstract][Full Text] [Related]
3. Activated microglia facilitate the transmission of α-synuclein in Parkinson's disease.
Zheng T; Zhang Z
Neurochem Int; 2021 Sep; 148():105094. PubMed ID: 34097990
[TBL] [Abstract][Full Text] [Related]
4. The central theme of Parkinson's disease: α-synuclein.
Ozansoy M; Başak AN
Mol Neurobiol; 2013 Apr; 47(2):460-5. PubMed ID: 23180276
[TBL] [Abstract][Full Text] [Related]
5. Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions.
Castonguay AM; Gravel C; Lévesque M
J Parkinsons Dis; 2021; 11(1):71-92. PubMed ID: 33104039
[TBL] [Abstract][Full Text] [Related]
6. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapeutic interventions in Parkinson's disease: Focus on α-Synuclein.
Ganguly U; Singh S; Chakrabarti S; Saini AK; Saini RV
Adv Protein Chem Struct Biol; 2022; 129():381-433. PubMed ID: 35305723
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
9. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
[TBL] [Abstract][Full Text] [Related]
10. Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies.
Fleming SM; Davis A; Simons E
Neuropharmacology; 2022 Jan; 202():108870. PubMed ID: 34742741
[TBL] [Abstract][Full Text] [Related]
11. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
Schulz-Schaeffer WJ
Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
[TBL] [Abstract][Full Text] [Related]
12. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease.
Galiano-Landeira J; Torra A; Vila M; Bové J
Brain; 2020 Dec; 143(12):3717-3733. PubMed ID: 33118032
[TBL] [Abstract][Full Text] [Related]
13. Targeting alpha-synuclein for the treatment of Parkinson's disease.
Rohn TT
CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285
[TBL] [Abstract][Full Text] [Related]
14. [Role of microglial activation induced by α-synuclein in pathogenesis of Parkinson's disease].
Qiao S; Luo JH; Jin JH
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Mar; 41(2):210-4. PubMed ID: 22499522
[TBL] [Abstract][Full Text] [Related]
15. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
[TBL] [Abstract][Full Text] [Related]
16. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
Daher JP
Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
[TBL] [Abstract][Full Text] [Related]
17. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
George S; Brundin P
J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
[TBL] [Abstract][Full Text] [Related]
19. α-Synuclein in Parkinson's disease: pathogenic function and translation into animal models.
Eschbach J; Danzer KM
Neurodegener Dis; 2014; 14(1):1-17. PubMed ID: 24080741
[TBL] [Abstract][Full Text] [Related]
20. Emerging disease-modifying strategies targeting α-synuclein for the treatment of Parkinson's disease.
O'Hara DM; Kalia SK; Kalia LV
Br J Pharmacol; 2018 Aug; 175(15):3080-3089. PubMed ID: 29722028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]